A randomized, Double-Blind, placebo-controlled, Single-Ascending-Dose and Multiple-Ascending-Dose study to evaluate the safety, tolerability and pharmacokinetics of RNV-166 in healthy male volunteers
Completed
This Phase 1 first-in-human clinical study evaluated the safety, tolerability, and pharmacokinetics of RNV-166 following single ascending dose (SAD) and multiple ascending dose (MAD) administration in healthy participants. Single oral doses of RNV-166 ranging from 200 mg to 1600 …
Phase 1 • Sponsor: InVitro Research Solutions Private Limited
Last updated Sep 09, 2026 17:00 UTC